<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01679223</url>
  </required_header>
  <id_info>
    <org_study_id>081512</org_study_id>
    <nct_id>NCT01679223</nct_id>
  </id_info>
  <brief_title>Incorporation of AlloMaxTM in Breast Reconstruction Ver8-15-12</brief_title>
  <official_title>Objective Evaluation of Collagen Deposition in AlloMaxTM Acellular Dermal Matrix in Breast Reconstruction Version 8-15-12</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Nevada, Las Vegas</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University of Nevada, Las Vegas</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to measure the level of AlloMaxâ„¢ incorporation (cellular
      infiltration, collagen production, and neovascularization) in human breast reconstruction.
      The hypothesis is that the AlloMaxTM will have incorporation equivalent to adjacent breast
      capsule at the 3-4 month time point.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>February 2014</start_date>
  <completion_date type="Anticipated">November 2018</completion_date>
  <primary_completion_date type="Anticipated">November 2018</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Case-Only</observational_model>
    <time_perspective>Cross-Sectional</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Hydroxyproline Concentration</measure>
    <time_frame>3-4 months</time_frame>
    <description>Hydroxyproline will be measured in the AlloMaxTM and adjacent capsule.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Neoangiogenesis</measure>
    <time_frame>3-4 months</time_frame>
    <description>Measure new blood vessels in AlloMaxTM and adjacent capsule</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Collagen I and III</measure>
    <time_frame>3-4 months</time_frame>
    <description>Measure collagen I and III in AlloMaxTM and adjacent capsule</description>
  </primary_outcome>
  <number_of_groups>3</number_of_groups>
  <enrollment type="Anticipated">60</enrollment>
  <condition>Breast Cancer</condition>
  <arm_group>
    <arm_group_label>&lt;40 years</arm_group_label>
    <description>subjects aged less than 40 years</description>
  </arm_group>
  <arm_group>
    <arm_group_label>40-60 years</arm_group_label>
    <description>subjects aged 40-60years</description>
  </arm_group>
  <arm_group>
    <arm_group_label>&gt; 60 years</arm_group_label>
    <description>subjects aged greater than 60 years</description>
  </arm_group>
  <eligibility>
    <study_pop>
      <textblock>
        Patients (18 - 70 yrs) scheduled for immediate two stage breast reconstruction with
        AlloMaxTM are potential subjects for this study
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Adult patients (18 - 70 yrs) who require reconstructive breast surgery with AlloMaxTM
             implants and agree to participate will be included in this study.

        Exclusion Criteria:

          -  Patients who do not agree to be included in the study.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Kayvan Taghipour-Khiabani, M.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Nevada School of Medicine</affiliation>
  </overall_official>
  <overall_official>
    <last_name>William A Zamboni, M.D.</last_name>
    <role>Study Chair</role>
    <affiliation>University of Nevada School of Medicine</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Kayvan Taghipour-Khiabani, M.D.</last_name>
    <phone>702-671-2267</phone>
    <email>kkhiabani@medicine.nevada.edu</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Shelley J Williams, M.S.</last_name>
    <phone>702-895-1445</phone>
    <email>sjwilliams@medicine.nevada.edu</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>University of Nevada School of Medicine</name>
      <address>
        <city>Las Vegas</city>
        <state>Nevada</state>
        <zip>89102-2227</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Sherree Mounts, LPN</last_name>
      <phone>702-671-5117</phone>
      <email>smounts@medicine.nevada.edu</email>
    </contact>
    <investigator>
      <last_name>Kayvan Taghipour-Khiabani, M.D.</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>William A Zamboni, M.D.</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Richard C Baynosa, M.D.</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>January 2015</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>August 31, 2012</study_first_submitted>
  <study_first_submitted_qc>August 31, 2012</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 5, 2012</study_first_posted>
  <last_update_submitted>January 8, 2015</last_update_submitted>
  <last_update_submitted_qc>January 8, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">January 9, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of Nevada, Las Vegas</investigator_affiliation>
    <investigator_full_name>Kayvan Taghipour-Khiabani, M.D.</investigator_full_name>
    <investigator_title>Tenured Associate Professor, Head of Hand and Microsurgery</investigator_title>
  </responsible_party>
  <keyword>Breast reconstruction</keyword>
  <keyword>Hydroxyproline concentration</keyword>
  <keyword>neoangiogenesis</keyword>
  <keyword>collagen deposition</keyword>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

